Edition:
United States

Novartis AG (NVS.N)

NVS.N on New York Stock Exchange

86.12USD
20 Sep 2017
Change (% chg)

$0.27 (+0.31%)
Prev Close
$85.85
Open
$86.21
Day's High
$86.25
Day's Low
$86.07
Volume
32,165
Avg. Vol
319,896
52-wk High
$86.90
52-wk Low
$66.93

Latest Key Developments (Source: Significant Developments)

Thrombogenics regains global rights to Jetrea
Monday, 18 Sep 2017 01:30am EDT 

Sept 18 (Reuters) - THROMBOGENICS NV ::THROMBOGENICS NV : THROMBOGENICS REGAINS GLOBAL RIGHTS TO JETREA (OCRIPLASMIN).‍ALCON AND NOVARTIS WILL WORK CLOSELY WITH THROMBOGENICS TO ENSURE CONTINUITY AND ACCESS TO JETREA FOR CUSTOMERS..UNDER THE TERMS OF THE AGREEMENT, THROMBOGENICS RECEIVES A CASH AMOUNT OF €53.7 MILLION AND A FORTHCOMING EQUITY INVESTMENT OF €10 MILLION IN THROMBOGENICS CAPITAL. ​.  Full Article

Novartis Pharma reports a 6.6 percent passive stake in Xoma Corp as of August 24, 2017
Tuesday, 5 Sep 2017 05:31pm EDT 

Sept 5 (Reuters) - Novartis AG :Novartis Pharma AG reports a 6.6 percent passive stake in Xoma Corp as of august 24, 2017 - SEC filing‍​.  Full Article

Novartis receives FDA approval for CAR-T cell therapy Kymriah
Wednesday, 30 Aug 2017 11:45am EDT 

Aug 30 (Reuters) - Novartis AG ::Novartis receives first ever FDA approval for a CAR-T cell therapy, Kymriah™ (tisagenlecleucel, CTL019), for children and young adults with B-cell ALL that is refractory or has relapsed at least twice.  Full Article

FDA approves first gene therapy available in the United States
Wednesday, 30 Aug 2017 11:02am EDT 

Aug 30 (Reuters) - U.S. Food and Drug Administration: :Says approved Kymriah (tisagenlecleucel) for certain pediatric and young adult patients with a form of acute lymphoblastic leukemia ‍​.Also expanded approval of Actemra (tocilizumab) to treat CAR T-cell-induced severe or life-threatening CRS in patients 2 yrs of age/older‍​.Says granted approval of Kymriah to Novartis Pharmaceuticals Corp and granted the expanded approval of Actemra to Genentech Inc‍​.Treatment with Kymriah has the potential to cause severe side effects, it carries a boxed warning for cytokine release syndrome (CRS).  Full Article

U.S. files lawsuit against US Bioservices related to kickbacks, Novartis' Exjade
Tuesday, 22 Aug 2017 09:19am EDT 

Aug 22 (Reuters) - U.S. SAYS U.S. BIOSERVICES ARRANGED TO RECEIVE MORE PATIENT REFERRALS AND RELATED BENEFITS IN RETURN FOR ACHIEVING HIGHER PRESCRIPTION REFILL RATE FOR EXJADE:.  Full Article

GSK non-core tail brands could sell for 0.5-1.0 bln pounds
Wednesday, 26 Jul 2017 10:45am EDT 

July 26 (Reuters) - GlaxoSmithKline CFO Simon Dingemans tells analysts::c.130 non-core tail brands with annual sales of 0.5 billion stg could sell for 1-2x sales.  Full Article

GSK CEO comments on Q2 results, business priorities
Wednesday, 26 Jul 2017 07:31am EDT 

July 26 (Reuters) - GlaxoSmithKline CEO Emma Walmsley told reporters::Ceo says absolutely committed to three-business structure of group.Ceo says business model provides stability of cash flows.Ceo says says will make progressive withdrawal from tanzeum diabetes business in u.s..Ceo says one m&a area where will be quite focused is early-stage pharma deals to bolster pipeline.Ceo says should not expect research and development budget to come down as result of pipeline review.Ceo says research and development spend per drug asset has been too low in the past.Ceo says does not want to put a number on future potential job losses.Ceo says encouraged by more pragmatic approach from uk government on brexit following recent letter from ministers.Ceo says.Ceo says wants long brexit transition and as much mutual drug recognition as possible.Ceo says absolute minimum brexit transition period needs to be 2 years, would like it to be longer.Ceo says partnership could be an option for oncology research and development assets.Ceo says would be 'delighted' to take on rest of consumer business but sale of stake up to novartis.Ceo says consolidation of u.s. Payers means pressure on drug prices will continue.  Full Article

Cryoport says Novartis signed agreement contracting co over an initial three-year term for cryogenic logistics support
Tuesday, 25 Jul 2017 07:00am EDT 

July 25 (Reuters) - Cryoport Inc :Cryoport - Novartis signed agreement contracting co over an initial three-year term for cryogenic logistics support of CTL019/CD19 CAR-T cell therapy.  Full Article

Amgen says FDA accepts biologics license application for Aimovig
Thursday, 20 Jul 2017 04:30pm EDT 

July 20 (Reuters) - Amgen Inc :FDA accepts biologics license application for Aimovig™ (erenumab).Amgen Inc - FDA has set a prescription drug user fee act (PDUFA) target action date of May 17, 2018..Amgen Inc - Aimovig will be jointly commercialized in U.S. by Amgen and Novartis..  Full Article

Novartis 'cooperating fully' with DOJ, SEC probe of Alcon's Russia, Asia business
Tuesday, 18 Jul 2017 09:28am EDT 

July 18 (Reuters) - Novartis Ag :Says generic dermatology portfolio was hit more severely by u.s. Price pressure as competitors introduced.Ceo says capital market exit for alcon would hinge on 'a few quarters' of growth.Alcon head says intraocular lens issues have stabilized but situation likely to be bumpy in next quarters, 'not declaring victory'.Sandoz head says reception for biosimilar rituximab has been good two weeks after launch.Alcon head says market share losses stabilizing in contact lenses, now on 'a bit of a winning trend'.Cancer unit head says looking at outcomes-based models for pricing cancer cell therapy ctl019, will disclose at launch of product.Cfo says roche stake continues to be a financial investment with strategic component, seeks to maximize value of holding.Says two-thirds of entresto patients are on u.s. Government insurance program medicare.Sandoz unit head says expects speedy rollout of rituximab biosimilar.Ceo says does not know timing of trump administration action on outcomes-based pricing model, expects proposal 'this summer'.Ceo says valuations for m&a make it difficult to find acquisitions between $2 billion-$5 billion that add value, still focused on bolt-on targets to strengthen oncology or differentiated generics business.Alcon head says received u.s. Doj, sec subpoena focusing on alcon's asia and Russia business, covers period before and after novartis owned the business, says cooperating fully.  Full Article

Photo

Novartis's Rydapt wins EU approval for AML, other diseases

ZURICH Swiss drugmaker Novartis on Wednesday won European Union approval for Rydapt to be used against a mutated form of acute myeloid leukemia (AML) and other rare diseases, adding to U.S. approvals the medicine secured in April.